title: Tumor Necrosis Factor-like Cytokine TL1A and Its Receptors DR3 and DcR3: Important New Factors in Mucosal Homeostasis and Inflammation.
abstract: Tumor necrosis factor (TNF)-like cytokine 1A (TL1A) is a member of the TNF superfamily of proteins (TNFSF15), which signals through association with death domain receptor 3 (DR3). Decoy receptor 3 (DcR3) competes with DR3 for TL1A binding and inhibits functional signaling. These proteins are significantly upregulated in inflamed intestinal tissues, and their pathogenetic importance for inflammatory bowel disease (IBD) is suggested by accumulating evidence. TL1A/DR3 induce costimulatory signals to activated lymphocytes, including the gut-specific populations of CD4+CD161+ and CD4+CCR9+ cells, affecting all major effector pathways and inducing the mucosal upregulation of Th1, Th2, and Th17 factors. They may also participate in mucosal homeostasis and defense against pathogens through their effects on the development and function of the recently described innate lymphoid cells. T-regulatory lymphocytes highly express DR3, and they respond to TL1A stimulation also. Mechanistic studies by transgenic expression of TL1A, deletion of TL1A or DR3, and therapeutic blockade by anti-TL1A antibodies all support the critical involvement of the corresponding pathways in the pathogenesis of chronic mucosal inflammation. Wide genome association studies have identified IBD-specific polymorphisms in TNFSF15 gene, which have functional implications and serve as poor prognostic factors. Recently, TL1A blockade in mice was presented as a unique pharmacological treatment for the reversal of established intestinal fibrosis. Finally, TL1A/DR3 signaling seems to critically participate in extraintestinal inflammatory conditions that are frequently associated with IBD as part of the gut-joint-skin-eye axis. These converging lines of evidence make TL1A/DR3 a suitable model for personalized approaches to IBD therapy.
authors.affiliation: Laikon Hospital, Academic Department of Gastroenterology, Kapodistrian University of Athens, Athens, Greece.
authors.forename: Spyros I
authors.initials: SI
authors.lastname: Siakavellas
authors.forename: Giorgos
authors.initials: G
authors.lastname: Bamias
mesh_terms: D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000378:metabolism; D006706:Homeostasis; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000503:physiopathology; D015212:Inflammatory Bowel Diseases / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology*; D007413:Intestinal Mucosa / Q000378:metabolism / Q000503:physiopathology*; D051379:Mice; D053219:Receptors, Tumor Necrosis Factor, Member 25 / Q000378:metabolism*; D053323:Receptors, Tumor Necrosis Factor, Member 6b / Q000378:metabolism*; D015398:Signal Transduction; D006377:T-Lymphocytes, Helper-Inducer / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000378:metabolism; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15 / Q000378:metabolism*; D015854:Up-Regulation
chemical_list: D053219:Receptors, Tumor Necrosis Factor, Member 25; D053323:Receptors, Tumor Necrosis Factor, Member 6b; C506033:TNFRSF25 protein, human; C505911:TNFRSF6B protein, human; C117026:TNFSF15 protein, human; D053380:Tumor Necrosis Factor Ligand Superfamily Member 15